Thymalin results: what to expect and when
A calf thymus extract studied for immune problems, with uncertain safety and product identity.
Also called: Timalin, Thymalinum, Thymaline, Тималин.
Khavinson bioregulator peptides · Calf-thymus polypeptide extract.
The 156 possible clinical reports include older records without summaries and reports that may reuse participants. They are not 156 independent trials; dose and safety details are often missing.
Key studies
- COVID-19: 10-day injections: A small trial reported fewer hospital deaths; replication is needed. (source)
- COVID-19: five-day injections: Immune and inflammation markers improved in an open-label trial. (source)
- COVID-19 antibodies at 104 days: Antibody levels fell less after Thymalin; protection from reinfection was not tested. (source)
- COVID-19 antibodies at 200 days: A follow-up report described higher antibody levels after Thymalin. (source)
- COVID-19 immune markers at six days: Retrospective analysis of immune-marker changes, not a new survival trial. (source)
- COVID-19: clotting and mortality: A comparative report found lower mortality with Thymalin; causal certainty is low. (source)
Related to Thymalin
- Epitalon: A peptide with telomerase effects in cells, but no proof that people live longer.
- Pinealon: A peptide with unproven brain benefits and no established injection dose.
- Thymogen: A Russian peptide used for immune problems, with negative cancer trials.
- Vesugen: An experimental blood-vessel peptide with unclear benefits and poorly defined safety.
- Cortagen: A four-amino-acid brain peptide backed mainly by animal work and unverified patent claims.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Supply unlicensed medicinal products (specials), MHRA · 2025
- US Chem Labs - 669074 - 02/07/2024, FDA · 2024
- National registers of authorised medicines, EMA
- ИНСТРУКЦИЯ ПО МЕДИЦИНСКОМУ ПРИМЕНЕНИЮ ЛЕКАРСТВЕННОГО ПРЕПАРАТА ТИМАЛИН®
- Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases., Ashraf AR et al. · JAMA network open · 2024
- [Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin.]., Kuznik BI et al. · Advances in gerontology = Uspekhi gerontologii · 2022
- Prognosis of immune state following basic therapy and thymalin treatment in patients with severe COVID-19 infection, Kuznik et al. · Russian Journal of Immunology · 2022
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.